SCHEMBL1670886

SCHEMBL1670886

C1=CC2=Nc3ccccc3C2C=C1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.33
NOS3 P29474 3/20 0.33
NOS2 P35228 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29383163 1.00 NOS1 (0.33) NOS1NOS3NOS2
SCHEMBL29543849 0.75 ALDH1A1 (0.32)
SCHEMBL2332914 0.72 NOS1 (0.33) NOS1NOS3NOS2
SCHEMBL920381 0.72
SCHEMBL23917373 0.70 MAPK14 (0.37)
SCHEMBL7465174 0.70 NOS1 (0.32) NOS1NOS3NOS2
SCHEMBL26937469 0.68 GPR3 (0.40)
SCHEMBL4938 0.67 NOS1 (0.32) NOS1NOS3NOS2
SCHEMBL19999997 0.66 RAB9A (0.36)
SCHEMBL15679169 0.66 MAPT (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1733715-B1 Composition for dyeing keratinic fibres comprising a diamino-N,N-dihydro-pyrazolone derivative, a coupling agent and a heterocyclic direct dye OREAL (FR) 2010-01-27 EP claimed
US-7582121-B2 Composition for dyeing keratin fibers, comprising at least one diamino-N,N-dihydropyrazolone derivative, at least one coupler, and at least one heterocyclic direct dye L'OREAL S.A. (FR) 2009-09-01 US claimed
US-20070006398-A1 Composition for dyeing keratin fibers, comprising at least one diamino-N,N-dihydropyrazolone derivative, at least one coupler, and at least one heterocyclic direct dye L'OREAL S.A. (FR) 2007-01-11 US claimed
US-6326368-B1 PSYCHOLOGICAL DISORDERS DUPONT PHARMACEUTICALS COMPANY 2001-12-04 US claimed
EP-3938345-B1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE NOCION THERAPEUTICS INC (US) 2026-05-06 EP disclosed
US-20260116859-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-12589090-B2 Compounds and methods for the treatment of degenerative disorders AQUILUS PHARMACEUTICALS, INC. (US) 2026-03-31 US disclosed
US-20260060989-A1 Charged Ion Channel Blockers And Methods For Use NOCION THERAPEUTICS INC (US) 2026-03-05 US disclosed
EP-4048747-B1 SELF-STOPPING POLISHING COMPOSITION AND METHOD CMC MAT LLC (US) 2026-02-18 EP disclosed
US-12544357-B2 Compositions and methods for the treatment of Plasmodium falciparum malaria BROWN UNIVERSITY (US) 2026-02-10 US disclosed
US-20250367283-A1 MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT TSINGHUA UNIVERSITY (CN) 2025-12-04 US disclosed
US-20250270189-A1 Ester Substituted Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2025-08-28 US disclosed
US-20090137566-A1 Substituted Piperdines as Renin Inhibitors EHARA TAKERU 2009-05-28 US disclosed
US-7267925-B2 Photosensitive composition and novel compound used therefor FUJIFILM CORPORATION (JP) 2007-09-11 US disclosed
US-7267925-B2 Photosensitive composition and novel compound used therefor FUJIFILM CORPORATION (JP) 2007-09-11 US disclosed
US-20070140973-A1 CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY 2007-06-21 US disclosed
EP-1399577-B1 METHOD FOR PRODUCING L-AMINO ACIDS SHOWA DENKO KK (JP) 2007-02-07 EP disclosed
US-20070015087-A1 Photosensitive composition FUJI PHOTO FILM CO., LTD. 2007-01-18 US disclosed
US-20070015087-A1 Photosensitive composition FUJI PHOTO FILM CO., LTD. 2007-01-18 US disclosed
US-20070006398-A1 Composition for dyeing keratin fibers, comprising at least one diamino-N,N-dihydropyrazolone derivative, at least one coupler, and at least one heterocyclic direct dye L'OREAL S.A. (FR) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544357-B2 Compositions and methods for the treatment of Plasmodium falciparum malaria PFN1, PFKP, FGB NOS1 3077/4885NOS3 2582/4885NOS2 3498/4885
US-20250367283-A1 MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT COASY, GGPS1, HMGCR NOS1 3589/4885NOS3 3764/4885NOS2 3379/4885
US-12589090-B2 Compounds and methods for the treatment of degenerative disorders CASP3, CASP10, CASP1 NOS1 383/4885NOS3 42/4885NOS2 380/4885
US-20090137566-A1 Substituted Piperdines as Renin Inhibitors REN, ACE, AGTR1 NOS1 1303/4885NOS3 1638/4885NOS2 1787/4885
US-20260060989-A1 Charged Ion Channel Blockers And Methods For Use TRPV1, TRPA1, TRPV2 NOS1 840/4885NOS3 936/4885NOS2 741/4885
US-20070006398-A1 Composition for dyeing keratin fibers, comprising at least one diamino-N,N-dihydropyrazolone derivative, at least one coupler, and at least one heterocyclic direct dye KRT18, DSP, DSG1 NOS1 1283/4885NOS3 1503/4885NOS2 1647/4885
US-20260116859-A1 Charged Ion Channel Blockers and Methods for Use OPRL1, TRPV1, SCN2B NOS1 1200/4885NOS3 1006/4885NOS2 1344/4885
US-20250270189-A1 Ester Substituted Ion Channel Blockers and Methods for Use TRPV1, TRPA1, TRPV2 NOS1 1391/4885NOS3 932/4885NOS2 1145/4885
US-20070140973-A1 CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING TNNI3, TNNT2, TNNC1 NOS1 3199/4885NOS3 3015/4885NOS2 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.